Excimer laser coronary angioplasty combined with drug‐coated balloon in the treatment of in‐stent restenosis

再狭窄 医学 血管成形术 经皮冠状动脉介入治疗 支架 靶病变 置信区间 气球 临床终点 人口 外科 药物洗脱支架 病变 放射科 内科学 随机对照试验 心肌梗塞 环境卫生
作者
Pan He,Haiwei Chen,Junjie Yang,Lei Gao,Jun Guo,Yundai Chen,Q Wang
出处
期刊:Lasers in Surgery and Medicine [Wiley]
卷期号:56 (5): 474-484 被引量:2
标识
DOI:10.1002/lsm.23794
摘要

Abstract Objectives The aim of this study is to investigate the safety and efficacy of excimer laser coronary angioplasty (ELCA) combined with drug‐coated balloons (DCBs) in the treatment of in‐stent restenosis (ISR), and to explore whether the contrast injection technique would improve the neointimal tissue ablation of ELCA. Methods We studied patients diagnosed with ISR between January 2019 and October 2022 at two medical centers. These patients underwent DCB angioplasty guided by optical coherence tomography (OCT). Based on whether ELCA was performed before DCB treatment, patients were categorized into two groups: the ELCA + DCB group and the DCB group. All patients underwent clinical follow‐up 1 year after the procedure. The primary endpoint was the 1‐year rate of target lesion revascularization (TLR), which was defined as any repeat percutaneous intervention or bypass surgery on the target vessel conducted to address restenosis or other complications related to the target lesion. The secondary endpoints including immediate luminal gain (ΔMLA, defined as the difference in minimum lumen area before and after the intervention). Results A total of 85 lesions in 75 patients were included. The mean age of the study population was 64.2 ± 12.0 years, with 81.3% male. Baseline clinical characteristics were well‐balanced, and procedural success was 100% in both groups. The ELCA + DCB group ( n = 24) exhibited a greater ΔMLA compared to the DCB group ( n = 61) (3.57 ± 0.79 mm² vs. 2.50 ± 1.06 mm², [95% confidence interval, CI: 0.57–1.69], p < 0.001), The reduction in 1‐year TLR was more frequently observed in patients from the ELCA + DCB group compared to the DCB group (hazard ratio 0.33 [95% CI: 0.11–0.99]; log‐rank p = 0.048). The exploratory analysis showed that ELCA with contrast infusion is associated with greater acute lumen gain compared to ELCA with saline infusion ( p < 0.001). Conclusions The combination of ELCA and DCB is a safe and effective treatment strategy for in‐stent stenosis. Additionally, compared with saline injection, ELCA with contrast injection is associated with greater acute lumen gain. However, the optimal contrast agent concentration and long‐term outcome of the contrast injection technique need confirmation through larger sample sizes and prospective studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
whh发布了新的文献求助10
1秒前
1秒前
冷艳的易槐完成签到,获得积分10
2秒前
accept来完成签到,获得积分20
2秒前
陈呱呱发布了新的文献求助10
3秒前
3秒前
长情晓兰发布了新的文献求助10
3秒前
su发布了新的文献求助10
4秒前
4秒前
九九发布了新的文献求助10
4秒前
5秒前
科研通AI5应助LBB采纳,获得10
5秒前
6秒前
yznfly举报chlgkmoney求助涉嫌违规
6秒前
隐形曼青应助呆萌的正豪采纳,获得10
6秒前
科研xiao白完成签到,获得积分10
7秒前
隐形曼青应助accept来采纳,获得10
7秒前
量子星尘发布了新的文献求助10
8秒前
sxd完成签到,获得积分10
9秒前
9秒前
田様应助嗯哼采纳,获得10
10秒前
10秒前
10秒前
研友_VZG7GZ应助Peggy69采纳,获得10
10秒前
yhp发布了新的文献求助10
10秒前
jason完成签到,获得积分10
10秒前
恢复出厂设置完成签到,获得积分10
10秒前
11秒前
11秒前
饶子阳完成签到,获得积分20
12秒前
高大的问丝完成签到,获得积分10
12秒前
九九完成签到,获得积分10
13秒前
13秒前
13秒前
君臣发布了新的文献求助10
15秒前
陈烨颖发布了新的文献求助10
15秒前
荒野乱斗发布了新的文献求助10
16秒前
17秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
SOFT MATTER SERIES Volume 22 Soft Matter in Foods 1000
Zur lokalen Geoidbestimmung aus terrestrischen Messungen vertikaler Schweregradienten 1000
Rapid synthesis of subnanoscale high-entropy alloys with ultrahigh durability 666
Storie e culture della televisione 500
Selected research on camelid physiology and nutrition 500
《2023南京市住宿行业发展报告》 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4886989
求助须知:如何正确求助?哪些是违规求助? 4171992
关于积分的说明 12947241
捐赠科研通 3932679
什么是DOI,文献DOI怎么找? 2157729
邀请新用户注册赠送积分活动 1176229
关于科研通互助平台的介绍 1080576